New York, May 26, 2026, 04:13 EDT
Lexaria Bioscience Corp. will open for normal Nasdaq trading on Tuesday after closing Friday at $0.65. Shares climbed 7.33% in the last full session before the Memorial Day holiday. Regular trading restarts at 9:30 a.m. Eastern, with pre-market open at 4 a.m.
Lexaria’s move is now in focus as its next test takes aim at the fast-growing oral obesity drug space. GLP-1 medicines that copy a gut hormone for hunger and blood sugar are a big market, dominated by Novo Nordisk and Eli Lilly.
Lexaria said May 19 an independent review board signed off on Human Pilot Study #7. The study will compare two DehydraTECH-semaglutide pills to Novo Nordisk’s Wegovy tablets. DehydraTECH is Lexaria’s delivery tech, used to get oral drugs into the bloodstream faster. Dosing should start in mid-June, according to the company.
Lexaria CEO Richard Christopher said the company was “delighted” by how fast ethics approval came through and said the study is aimed at backing commercial work with bigger drug makers. The trial is set to look at safety, tolerability, and pharmacokinetics, or how the drug travels in and is measured by the body.
Lexaria’s management is still pushing the partner angle. In a video for investors out May 7, CEO Christopher pointed to a separate pharma deal extension as proof of “continued engagement around DehydraTECH.” He also said the company is focusing on clinical results and ongoing talks with possible GLP-1 partners. Lexaria Bioscience
Competition is tough. Reuters said this month that cheaper oral weight-loss drugs from Novo Nordisk and Eli Lilly are pulling some patients from compounded options. Trial data showed oral Wegovy cut body weight around 14% over 64 weeks, while Lilly’s Foundayo lowered it about 11% over 72 weeks.
Lexaria isn’t offering a weight-loss drug. The company wants to show that its drug delivery tech can help oral drugs work better or cut side effects. That puts it up against big firms with approved products and heavy sales staff.
Lexaria said April 29 it has extended a material transfer agreement with an unnamed pharmaceutical company through Dec. 31, 2026. The extension lets the partner look at 2026 GLP-1 research results. Lexaria expects to report results from related studies in the third and fourth quarters.
Downside risks are on the table. A weak or delayed study might pressure the stock, especially if results miss established oral semaglutide drugs or fail to lead to a licensing deal. Lexaria’s most recent 10-Q reported a $3.0 million net loss for the six months ended Feb. 28, cash of $5.1 million, and a $66.5 million accumulated deficit. The filing said there was “substantial doubt” about whether the company can stay in business without more funding. SEC
Lexaria has a listing issue, too. Back in February, the company said Nasdaq gave it notice for slipping under the $1 minimum bid price. Lexaria has until Aug. 3 to get back in line, which means the stock has to close at $1 or higher for at least 10 business days in a row.
Stock watchers have a basic test this week: can Friday’s bounce stick after the long weekend. The more important hurdle is still ahead, with investors focused on early-June quality-control completion and mid-June dosing for Study #7.
